Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single‐blind, placebo‐controlled study in F2/F3 NASH

Rencofilstat (RCF) demonstrated antifibrotic effects in preclinical models and was safe and well tolerated in Phase 1 studies. The aim of this Phase 2a study was safety, tolerability, pharmacokinetics, and exploration of efficacy biomarkers in subjects with nonalcoholic steatohepatitis (NASH). This...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Stephen A., Mayo, Patrick R., Hobbs, Todd M., Canizares, Carlos, Foster, Erin P., Zhao, Caroline, Ure, Daren R., Trepanier, Daniel J., Greytok, Jill A., Foster, Robert T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701462/
https://www.ncbi.nlm.nih.gov/pubmed/36271849
http://dx.doi.org/10.1002/hep4.2100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701462/
https://www.ncbi.nlm.nih.gov/pubmed/36271849
http://dx.doi.org/10.1002/hep4.2100

Ejemplares similares